Market Cap
$39.26 Billion
USD as of Jan. 1, 2023
Company | Market Cap (USD) |
---|---|
![]() |
$461.85 B |
![]() |
$347.61 B |
![]() |
$287.63 B |
![]() |
$285.80 B |
![]() |
$281.30 B |
Company | Market Cap (USD) |
---|---|
![]() |
$495.37 B |
![]() |
$461.85 B |
![]() |
$347.61 B |
![]() |
$304.61 B |
![]() |
$287.63 B |
Biogen Inc. is a biotechnology company specialized in the treatment of neurological diseases. It researches, develops, and markets therapies for a range of diseases including Alzheimer’s disease, hemophilia, multiple sclerosis, spinal muscular atrophy, plaque psoriasis, leukemia, rheumatoid arthritis, lymphoma, neurocognitive disorders, and pain.
Biogen Inc. has the following listings and related stock indices.
Stock: NASDAQ: BIIB
Stock: BCBA: BIIB
Stock: BMV: BIIB
Stock: Bovespa: BIIB34
Stock: BVS: BIIB
Stock: FSX: IDP
Stock: MTA: BIIB.U
The market capitalization of a company, more simply referred to as "market cap", is the total market value of a publicly traded company's outstanding shares. It is often considered as a key indicator of what a company is worth.